Century Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Century Therapeutics, Inc. (Nasdaq: IPSC), an emerging growth company, on January 7, 2026. The report details the entry into a material definitive agreement for a private placement of equity securities.
Key Financial Metrics and Transaction Details
The filing does not provide historical revenue, profit, cash flow, or margin data as it is a current report regarding a specific transaction rather than a periodic financial statement. Key transaction metrics include:
- Gross Proceeds: Approximately $135.0 million expected from the private placement.
- Securities Issued:
- 92,030,595 shares of Common Stock and/or Pre-Funded Warrants.
- Pre-Funded Warrants to purchase 25,360,704 shares of Common Stock.
- Common Warrants to purchase 58,695,648 shares of Common Stock or Pre-Funded Warrants.
- Purchase Price: $1.15 per share of Common Stock; $1.1499 per Pre-Funded Warrant.
- Warrant Terms: Common Warrants have an exercise price of $2.60 per share (or $2.599 per Pre-Funded Warrant) and expire 30 days after the public announcement of initial Phase 1 clinical data for CNTY-813 or on the third anniversary of the closing, whichever is earlier.
Material Changes and Use of Proceeds
The primary material change is the capital raise via private placement. The Company intends to use the net proceeds to fund the development of its lead product candidate, CNTY-813, and for working capital and other general corporate purposes. The transaction is expected to close on or about January 9, 2026.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The capital raise is designed to support the clinical development of CNTY-813. The Company has entered into a lock-up agreement, agreeing not to issue additional equity or file registration statements for 30 days post-closing or until the registration statement for the private placement shares is effective, whichever is earlier.
Risks and Contingencies:
- Registration Rights: The Company must file a registration statement for the resale of shares within 30 days of closing. Failure to file or have the statement declared effective within specific timelines (ranging from 5 to 90 days post-closing depending on SEC review status) triggers liquidated damages of 1% of the investment per 30-day period.
- Warrant Expiration: The Common Warrants have a unique expiration tied to clinical data milestones, creating a specific timeline for potential dilution.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received after deducting placement agent fees and offering expenses.
- Confirm the filing and effectiveness date of the registration statement for the Private Placement Shares to assess potential liquidated damages risk.
- Monitor the timeline for the public announcement of initial Phase 1 clinical data for CNTY-813, as this triggers the expiration of Common Warrants.
- Review the full text of the Securities Purchase Agreement and Registration Rights Agreement (Exhibits 10.1 and 10.2) for specific caps on liquidated damages and other covenants.